Weekly Recap: Merger registration takes effect and Microfluidics unit sold
Waktu baca kurang dari 1 menit
Standard BioTools Inc. (NASDAQ:LAB) completed the sale of its Microfluidics Business to ARCHIMED on Nov. 3, 2026, and the unit now operates independently as Biomark Scientific. The merger registration with Treeline took effect Oct. 21, with shareholders set to vote Nov. 19 and closing expected in Q4 2026.
Previous Week Recap
- Merger Vote And Q4 Closing: Standard BioTools’ (LAB) merger registration with Treeline took effect Oct. 21. Shareholders vote Nov. 19, with closing expected in Q4 2026. TradingView
- Microfluidics Sale Completed To ARCHIMED: Standard BioTools (LAB) completed the sale of its Microfluidics Business to ARCHIMED on Nov. 3, 2026. The unit now operates independently as Biomark Scientific, supporting its products and services. 2 sumber
- Cost Cuts Extend Liquidity Runway: Standard BioTools (LAB) said job cuts and consolidating Singapore R&D lowered costs. Its available liquidity is expected to cover operations for at least 12 months. TradingView
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.